GlaxoSmithKline Discontinues Clinical Development Of Investigational Protease Inhibitor Brecanavir

GlaxoSmithKline plc (GSK) today confirms that, due to insurmountable issues regarding formulation, development of brecanavir, an investigational protease inhibitor for the treatment of HIV, has been discontinued. Brecanavir was in phase II clinical development.


Clinical trial investigators have been notified and directed to transition their patients to marketed antiretrovirals, or appropriate treatments available through expanded access programmes.


???GSK is dedicated to excellence in the care of individuals with HIV infection, and we will continue our efforts to find effective treatments with improved resistance profiles for these patients,??? said Lynn Marks, MD, Senior Vice President, GSK Medicine Development Centre for Infectious Diseases. ???Despite this disappointing outcome with brecanavir, we remain unwavering in our commitment to find new solutions to meet the challenges of HIV/AIDS.???


GlaxoSmithKline one of the world??™s leading research-based pharmaceutical and healthcare companies is committed to improving the quality of human life by enabling people to do more, feel better and live longer.


Cautionary statement regarding forward-looking statements


Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report on Form 20-F for 2005.


GlaxoSmithKline

gsk/